<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876601</url>
  </required_header>
  <id_info>
    <org_study_id>LPS_DF Version 1.4</org_study_id>
    <nct_id>NCT02876601</nct_id>
  </id_info>
  <brief_title>Defibrotide in the Human Endotoxemia Model --‐ an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide</brief_title>
  <acronym>LPS_DF</acronym>
  <official_title>Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernd Jilma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Defibrotide is an anti-inflammatory and anti-coagulatory agent approved for treatment of
      veno-occlusive disease. Although it has been in clinical use for almost 30 years, the exact
      mechanism of action has never been fully elucidated. Thus, the effects of defibrotide will be
      investigated in the human endotoxemia model in order to gather further information on its
      actions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Defibrotide (DF) is a highly complex polydisperse mixture of single-stranded phosphodiester
      oligodeoxyribonucleotides derived from the controlled depolymerization of porcine intestinal
      mucosal DNA. The entire mode of action remains unknown. Its actions may be summarized to
      pro-fibrinolytic, anti-inflammatory and anti-coagulatory actions. To better define the
      mechanisms of Defibrotide the effects of the substance will be investigated in the
      well-established endotoxemia model. Sixteen healthy volunteers will be randomized to receive
      LPS±defibrotide/placebo and four subjects will be randomized to receive Placebo±
      defibrotide/placebo in a single center, randomized, double blind, placebo controlled, two-way
      crossover trial. Immediately after a 2h infusion of 6,25mg/kg bodyweight defibrotide or
      placebo a LPS bolus of 2ng/kg bodyweight will be infused. Analyses will be performed by blood
      sampling at pre-defined time-points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">February 12, 2018</completion_date>
  <primary_completion_date type="Actual">February 12, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive LPS (n=16) or placebo (n=4) first. In each group they will undergo two study periods (crossover trial): a placebo period and a defibrotide period. The placebo group (n=4) will only be analyzed descriptively.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prothrombin Fragments f1+2</measure>
    <time_frame>The parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombin-Antithrombin Complexes</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmin-Antiplasmin Complexes</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, and 6h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor (TNF)-Alpha</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue-type Plasminogen Activator</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E-Selectin</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor 1</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Von Willebrand Factor Antigen</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The quantification of von Willebrand Factor is based on reference values and results are in % of &quot;normal&quot;.
The respective arbitrary unit therefore is %*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clotting Time in Thromboelastometry</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
    <description>In this analysis, first of all a ratio of the measurement time point to the baseline was calculated. Thereafter deltas (baeline-ratio) were calculated. With the results an AUC was calculated.
The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Lysis in Thromboelastometry</measure>
    <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h and AUC was calculated based on these measurements.</time_frame>
    <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Endotoxemia</condition>
  <arm_group>
    <arm_group_label>Defibrotide/LPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/LPS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Defibrotide/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>6.25mg/kg bodyweight over 2h infusion</description>
    <arm_group_label>Defibrotide/LPS</arm_group_label>
    <arm_group_label>Defibrotide/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% sodium chloride)</intervention_name>
    <description>(0.9% sodium chloride) infusion over 2h infusion</description>
    <arm_group_label>Placebo/LPS</arm_group_label>
    <arm_group_label>Placebo/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipopolysaccharide</intervention_name>
    <description>bolus infusion of 2ng/kg bodyweight lps</description>
    <arm_group_label>Defibrotide/LPS</arm_group_label>
    <arm_group_label>Placebo/LPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% sodium chloride bolus)</intervention_name>
    <description>(0.9% sodium chloride) bolus infusion</description>
    <arm_group_label>Defibrotide/Placebo</arm_group_label>
    <arm_group_label>Placebo/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years of age

          -  &lt;90kg body weight

          -  Normal findings in medical history and physical examination unless the investigator
             considers the abnormality to be clinically irrelevant

          -  Normal laboratory values unless the investigator considers abnormalities to be
             clinically irrelevant

          -  Ability to understand the purpose and nature of the study, as well as the associated
             risks

        Exclusion Criteria:

          -  Intake of any drugs that may interfere with the trial's endpoints or drugs (i.e.
             platelet inhibitors, anticoagulants, etc.)

          -  Positive results of HIV or hepatitis virology

          -  Acute illness with systemic inflammatory reactions

          -  Known allergies, hypersensitivities or intolerances to any of the used substances

          -  Acute or recent bleeding episodes, increased risk of bleeding at the discretion of the
             investigator

          -  Participation in an LPS trial within 6 weeks of the first study day

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <results_first_submitted>August 18, 2019</results_first_submitted>
  <results_first_submitted_qc>December 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2019</results_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Bernd Jilma</investigator_full_name>
    <investigator_title>Ao.Univ.Prof.Dr.med</investigator_title>
  </responsible_party>
  <keyword>Coagulation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Defibrotide</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in a peer-reviewed medical journal, individual data will not be presented or published, but may be made available by direct request to the PI (data may be made available in an anonymized fashion)</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02876601/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a crossover study. Of 20 healthy volunteers 16 were randomly assigned to receive LPS, while 4 received Placebo only. All participants underwent two study periods: A defibrotide and a placebo period.
The system will not let us enter this study design of a crossover study. Only 20 healthy volunteers participated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LPS+ First Defibrotide, Then Placebo</title>
          <description>First Intervention:
LPS: 2ng/kg bodyweight Defibrotide: 6.25mg/kg bodyweight over 2h infusion
Washout for 6 weeks:
Second Intervention:
LPS: 2ng/kg bodyweight Placebo: 0.9% sodium chloride infusion over 2h infusion</description>
        </group>
        <group group_id="P2">
          <title>LPS+ First Placebo, Then Defibrotide</title>
          <description>First Intervention:
LPS: 2ng/kg bodyweight Placebo: 0.9% sodium chloride infusion over 2h infusion
Washout for 6 weeks:
Second Intervention:
LPS: 2ng/kg bodyweight Defibrotide: 6.25mg/kg bodyweight over 2h infusion</description>
        </group>
        <group group_id="P3">
          <title>Placebo+ First Defibrotide, Then Placebo</title>
          <description>4 healthy volunteers were randomized not to receive LPS. However, they still received Placebo or Defibrotide. This group was included as another control group and to investigate the effects of Defibrotide in vivo.
First Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Defibrotide: 6.25mg/kg bodyweight Defibrotide over 2 hours
Washout: 6 weeks
Second Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Placebo: 0.9% sodium chloride solution infusion over 2h</description>
        </group>
        <group group_id="P4">
          <title>Placebo+ First Placebo, Then Defibrotide</title>
          <description>4 healthy volunteers were randomized not to receive LPS. However, they still received Placebo or Defibrotide. This group was included as another control group and to investigate the effects of Defibrotide in vivo.
4 healthy volunteers were randomized not to receive LPS. However, they still received Placebo or Defibrotide. This group was included as another control group and to investigate the effects of Defibrotide in vivo.
First Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Placebo: 0.9% sodium chloride solution infusion over 2h
Washout: 6 weeks
Second Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Defibrotide: 6.25mg/kg bodyweight Defibrotide over 2 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (24 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (Minimum of 6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>unforeseen unavailability</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (24 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LPS+ First Defibrotide, Then Placebo</title>
          <description>First Intervention:
LPS: 2ng/kg bodyweight Defibrotide: 6.25mg/kg bodyweight over 2h infusion
Washout for 6 weeks:
Second Intervention:
LPS: 2ng/kg bodyweight Placebo: 0.9% sodium chloride infusion over 2h infusion</description>
        </group>
        <group group_id="B2">
          <title>LPS+ First Placebo, Then Defibrotide</title>
          <description>First Intervention:
LPS: 2ng/kg bodyweight Placebo: 0.9% sodium chloride infusion over 2h infusion
Washout for 6 weeks:
Second Intervention:
LPS: 2ng/kg bodyweight Defibrotide: 6.25mg/kg bodyweight over 2h infusion</description>
        </group>
        <group group_id="B3">
          <title>Placebo+ First Defibrotide, Then Placebo</title>
          <description>4 healthy volunteers were randomized not to receive LPS. However, they still received Placebo or Defibrotide. This group was included as another control group and to investigate the effects of Defibrotide in vivo.
First Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Defibrotide: 6.25mg/kg bodyweight Defibrotide over 2 hours
Washout: 6 weeks
Second Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Placebo: 0.9% sodium chloride solution infusion over 2h</description>
        </group>
        <group group_id="B4">
          <title>Placebo+ First Placebo, Then Defibrotide</title>
          <description>4 healthy volunteers were randomized not to receive LPS. However, they still received Placebo or Defibrotide. This group was included as another control group and to investigate the effects of Defibrotide in vivo.
4 healthy volunteers were randomized not to receive LPS. However, they still received Placebo or Defibrotide. This group was included as another control group and to investigate the effects of Defibrotide in vivo.
First Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Placebo: 0.9% sodium chloride solution infusion over 2h
Washout: 6 weeks
Second Intervention:
Placebo: bolus infusion of 0.9% sodium chloride solution Defibrotide: 6.25mg/kg bodyweight Defibrotide over 2 hours</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="9"/>
                    <measurement group_id="B2" value="29" spread="7"/>
                    <measurement group_id="B3" value="41" spread="8"/>
                    <measurement group_id="B4" value="21" spread="0"/>
                    <measurement group_id="B5" value="31" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prothrombin Fragments f1+2</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
        <time_frame>The parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo (0.9% sodium chloride) infusion placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Prothrombin Fragments f1+2</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold-change*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="16.96" upper_limit="61.6"/>
                    <measurement group_id="O2" value="34.08" lower_limit="20.38" upper_limit="60.8"/>
                    <measurement group_id="O3" value="27.41" lower_limit="27.21" upper_limit="46.48"/>
                    <measurement group_id="O4" value="36.02" lower_limit="23.64" upper_limit="51.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.408</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombin-Antithrombin Complexes</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus placebo bolus infusion (0.9%sodium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) plus placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombin-Antithrombin Complexes</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.39" lower_limit="15.19" upper_limit="32.52"/>
                    <measurement group_id="O2" value="27.4" lower_limit="21.47" upper_limit="41.57"/>
                    <measurement group_id="O3" value="17.46" lower_limit="15.58" upper_limit="20.46"/>
                    <measurement group_id="O4" value="21.83" lower_limit="16.09" upper_limit="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.148</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasmin-Antiplasmin Complexes</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, and 6h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide and 2ng/kg bodyweight LPS bolus</description>
          </group>
          <group group_id="O2">
            <title>LPS/Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) and 2ng/kg bodyweight LPS bolus</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide and Placebo bolus (0.9% sodium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) and placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasmin-Antiplasmin Complexes</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="9.59" upper_limit="15.12"/>
                    <measurement group_id="O2" value="9.99" lower_limit="8.15" upper_limit="13.16"/>
                    <measurement group_id="O3" value="7" lower_limit="6.31" upper_limit="7.19"/>
                    <measurement group_id="O4" value="7.12" lower_limit="6.34" upper_limit="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis Factor (TNF)-Alpha</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus 2ng/kg lipopolysaccharide bolus infusion</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus Placebo infusion (0.9% sodium chloride</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) plus placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor (TNF)-Alpha</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
          <population>The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286" lower_limit="162" upper_limit="453"/>
                    <measurement group_id="O2" value="326" lower_limit="172" upper_limit="366"/>
                    <measurement group_id="O3" value="28.08" lower_limit="22.19" upper_limit="28.35"/>
                    <measurement group_id="O4" value="21.01" lower_limit="16.75" upper_limit="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.642</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tissue-type Plasminogen Activator</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus 2ng/kg bodyweight lipopolysaccharide</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: Placebo infusion (0.9% sodium chloride) plus 2ng/kg bodyweight LPS</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: placebo bolus (0.9% sodium chloride) plus 6.25mg/kg bodyweight defibrotide</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo bolus (0.9% sodium chloride) plus placebo (0.9% sodium chloride) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue-type Plasminogen Activator</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" lower_limit="14.9" upper_limit="29.3"/>
                    <measurement group_id="O2" value="17" lower_limit="13.9" upper_limit="23.9"/>
                    <measurement group_id="O3" value="20.57" lower_limit="19.75" upper_limit="21.45"/>
                    <measurement group_id="O4" value="23.54" lower_limit="21.72" upper_limit="24.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus infusionbolus infusion of 2ng/kg bodyweight LPS</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: Bolus infusion of 2ng/kg bodyweight LPS plus Placebo (0.9% sodium chloride)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight Defibrotide infusion plus Placebo (0.9% sodium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: Placebo (0.9% sodium chloride) bolus infusion plus placebo (0.9% sodium chloride) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The respective arbitrary unit therefore is fold*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1543" lower_limit="815" upper_limit="2919"/>
                    <measurement group_id="O2" value="1144" lower_limit="22" upper_limit="1923"/>
                    <measurement group_id="O3" value="35" lower_limit="32" upper_limit="113"/>
                    <measurement group_id="O4" value="31" lower_limit="23" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.326</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E-Selectin</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: Defibrotide 6.25mg/kg infusion plus bolus infusion of 2ng/kg bodyweight LPS</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: placebo (0.9% sodium chloride) infusion plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide infusion plus placebo (0.9% sodium chloride) bolus infusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride) plus placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>E-Selectin</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="32" upper_limit="40"/>
                    <measurement group_id="O2" value="33" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="O3" value="21" lower_limit="18" upper_limit="36"/>
                    <measurement group_id="O4" value="41" lower_limit="20" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.796</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasminogen Activator Inhibitor 1</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide infusion plus 2ng/kg LPS bolus infusion</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: placebo (0.9% sodium chloride) infusion plus 2ng/kg bodyweight LPS</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus placebo (0.9% sodium chloride) infusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo (0.9% sodium chloride) infusion plus placebo (0.9% sodium chloride) bolus infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor 1</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" lower_limit="32" upper_limit="898"/>
                    <measurement group_id="O2" value="477" lower_limit="49" upper_limit="1000"/>
                    <measurement group_id="O3" value="25" lower_limit="25" upper_limit="29.5"/>
                    <measurement group_id="O4" value="24.86" lower_limit="22.7" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.918</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Von Willebrand Factor Antigen</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The quantification of von Willebrand Factor is based on reference values and results are in % of &quot;normal&quot;.
The respective arbitrary unit therefore is %*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: Placebo infusion (0.9% sodium chloride) plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotie</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide plus placebo bolus infusion (0.9% sodium chloride solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: Placebo (0.9% sodium chloride solution) infusion plus placebo bolus infusion (0.9% sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Von Willebrand Factor Antigen</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject. The quantification of von Willebrand Factor is based on reference values and results are in % of &quot;normal&quot;.
The respective arbitrary unit therefore is %*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison.</population>
          <units>%*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="41" upper_limit="70"/>
                    <measurement group_id="O2" value="53" lower_limit="41" upper_limit="65"/>
                    <measurement group_id="O3" value="27" lower_limit="27" upper_limit="31"/>
                    <measurement group_id="O4" value="26" lower_limit="24" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.877</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clotting Time in Thromboelastometry</title>
        <description>In this analysis, first of all a ratio of the measurement time point to the baseline was calculated. Thereafter deltas (baeline-ratio) were calculated. With the results an AUC was calculated.
The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h, 24h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight LPS plus bolus infusion of 2ng/kg bodyweight LPS</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride solution) plus bolus infusion of 2ng/kg bodyweight LPS</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight defibrotide infusion plus placebo (0.9% sodium chloride solution) bolus infusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo (0.9%sodium chloride solution) infusion plus placebo bolus infusion (0.9% sodium chloride solution)</description>
          </group>
        </group_list>
        <measure>
          <title>Clotting Time in Thromboelastometry</title>
          <description>In this analysis, first of all a ratio of the measurement time point to the baseline was calculated. Thereafter deltas (baeline-ratio) were calculated. With the results an AUC was calculated.
The respective arbitrary unit therefore is fold*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison.</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.8" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.04" upper_limit="1.41"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-6" upper_limit="2.17"/>
                    <measurement group_id="O4" value="2.14" lower_limit="0.31" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.423</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Lysis in Thromboelastometry</title>
        <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
        <time_frame>This parameter was assessed at baseline, at 0h, 1h, 2h, 4h, 6h and AUC was calculated based on these measurements.</time_frame>
        <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>LPS Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight infusion plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O2">
            <title>LPS Plus Placebo</title>
            <description>Intervention: placebo infusion (0.9% sodium chloride infusion) plus 2ng/kg bodyweight LPS bolus infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo Plus Defibrotide</title>
            <description>Intervention: 6.25mg/kg bodyweight infusion plus placebo (0.9% sodium chloride solution) bolus infusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo Plus Placebo</title>
            <description>Intervention: placebo (0.9% sodium chloride) infusion plus placebo (0.9% sodium chloride) bolus infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Lysis in Thromboelastometry</title>
          <description>Based on the changes from baseline an area-under the concentration-time curve will be calculated and will be compared between the placebo and the verum phase within each subject.
The respective arbitrary unit therefore is fold*h.</description>
          <population>The main statistical comparison was done for all subjects receiving LPS (defibrotide vs. placebo).
The &quot;placebo period&quot; (4 subjects who did not receive lipopolysaccharide) was only included for a descriptive comparison, but not for statistical comparison.</population>
          <units>fold*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="7.1" upper_limit="10.1"/>
                    <measurement group_id="O2" value="7.7" lower_limit="6.6" upper_limit="9"/>
                    <measurement group_id="O3" value="6.84" lower_limit="6.72" upper_limit="7.07"/>
                    <measurement group_id="O4" value="6.85" lower_limit="6.32" upper_limit="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.938</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the individual subject, adverse events were assessed during every study visit (screening, study day1, study day 2, follow up) during the whole study. The whole study period lastet for a minimum of 8 weeks, but could be longer for individual subjects (washout period was a minimum of 6 weeks). The respective time frame could therefore differ between the individual subjects but was a minimum of 8 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Defibrotide Plus LPS</title>
          <description>Intervention: 6.25mg/kg bodyweight defibrotide infusion plus 2ng/kg bodyweight LPS infusion</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus LPS</title>
          <description>Intervention: placebo infusion (0.9% sodium chloride solution) plus 2ng/kg bodyweight LPS infusion</description>
        </group>
        <group group_id="E3">
          <title>Defibrotide Plus Placebo</title>
          <description>Intervention: 6.25mg/kg bodyweight defibrotide infusion plus placebo bolus infusion (0.9% sodium chloride solution)</description>
        </group>
        <group group_id="E4">
          <title>Placebo/Placebo</title>
          <description>Intervention: placebo infusion (0.9% sodium chloride solution) plus placebo bolus infusion (0.9% sodium chloride solution)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Feeling Cold</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Impaired Concentration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Precollapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticarial rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Univ.Prof. Dr. Bernd Jilma</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>+4314040029810</phone>
      <email>bernd.jilma@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

